ID   HRG_RAT                 Reviewed;         525 AA.
AC   Q99PS8; D3ZJN0; Q99PS7; Q9ESB2;
DT   31-MAY-2011, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   24-JUL-2024, entry version 129.
DE   RecName: Full=Histidine-rich glycoprotein;
DE   AltName: Full=Histidine-proline-rich glycoprotein;
DE            Short=HPRG;
DE   AltName: Full=Histidine-rich glycoprotein 1;
DE            Short=HRG1;
DE   Flags: Precursor;
GN   Name=Hrg; Synonyms=Hrg1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND SUBCELLULAR LOCATION.
RC   STRAIN=Lewis;
RX   PubMed=10849117; DOI=10.1046/j.1440-1711.2000.00940.x;
RA   Hulett M.D., Parish C.R.;
RT   "Murine histidine-rich glycoprotein: cloning, characterization and cellular
RT   origin.";
RL   Immunol. Cell Biol. 78:280-287(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RA   Wakabayashi S., Takahashi K., Hirokado Y., Togo Y., Izumi S., Ohashi T.,
RA   Sato N., Hirata D., Tsuchida N., Koide T.;
RT   "Molecular diversity of mammalian histidine-rich glycoprotein.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-145 AND SER-438, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Plasma glycoprotein that binds a number of ligands such as
CC       heme, heparin, heparan sulfate, thrombospondin, plasminogen, and
CC       divalent metal ions. Inhibits rosette formation. Acts as an adapter
CC       protein and implicated in regulating many processes such as immune
CC       complex and pathogen clearance, cell adhesion, angiogenesis,
CC       coagulation and fibrinolysis. Mediates clearance of necrotic cells
CC       through enhancing the phagocytosis of necrotic cells in a heparan
CC       sulfate-dependent pathway. This process can be regulated by the
CC       presence of certain HRG ligands such as heparin and zinc ions. Binds to
CC       IgG subclasses of immunoglobins containing kappa and lambda light
CC       chains with different affinities regulating their clearance and
CC       inhibiting the formation of insoluble immune complexes. Tethers
CC       plasminogen to the cell surface. Binds T-cells and alters the cell
CC       morphology. Modulates angiogenesis by blocking the CD6-mediated
CC       antiangiongenic effect of thrombospondins, THBS1 and THBS2 (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with THBS1 (via the TSP type I repeats); the
CC       interaction blocks the antiangiogenic effect of THBS1 with CD36.
CC       Interacts with HPSE; the interaction is enhanced at acidic pH,
CC       partially inhibits binding of HPSE to cell surface receptors and
CC       modulates its enzymatic activity. Interacts (via the HRR domain) with
CC       TMP1; the interaction partially mediates the antiangiogenic properties
CC       of HRG. Interacts with kappa and lambda light chains of IgG molecules.
CC       Interacts with ATP5F1A; the interaction occurs on the surface of T-
CC       cells and alters their cell morphology in concert with CONA. Binds IgG
CC       molecules containing kappa and lambda light chains and inhibits the
CC       formation of insoluble immunoglobulin complexes. Interacts with F12;
CC       the interaction, which is enhanced in the presence of zinc ions and
CC       inhibited by heparin-binding to HRG, inhibits factor XII autoactivation
CC       and contact-initiated coagulation (By similarity). Interacts with PLG
CC       (via its Kringle domains); the interaction tethers PLG to the cell
CC       surface and enhances its activation. Interacts (via the HRR domain)
CC       with TPM1; the interaction appears to contribute to the antiangiogenic
CC       properties of the HRR domain. Interacts with THBS2; the interaction
CC       blocks the antiangiogenic effect of THBS2 with CD36 (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:10849117}.
CC   -!- TISSUE SPECIFICITY: Expressed in liver, blood plasma, serum and in
CC       platelets. Also present in fibrin clots, wound fluid from acute wounds
CC       and chronic leg ulcers. {ECO:0000269|PubMed:10849117}.
CC   -!- DOMAIN: The His-rich (HRR) region contains approximately 12 tandem
CC       internal repeats of the 5-residue G[H/P][H/P]PH consensus sequence. HRR
CC       binds heparan sulfate and possesses antiangiogenic, antibacterial and
CC       antifungal properties through binding Candida cells, and preferentially
CC       lysing the ergosterol-containing liposomes at low pH. The tandem
CC       repeats also bind divalent metal ions and heme (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The cystatin domains can also bind heparan sulfate. Binding is
CC       enhanced in the presence of zinc ions (By similarity). {ECO:0000250}.
CC   -!- PTM: N-glycosylated. {ECO:0000250}.
CC   -!- PTM: Proteolytic cleavage produces several HRG fragments which are
CC       mostly disulfide-linked and, therefore, not released. Cleavage by
CC       plasmin is inhibited in the presence of heparin, zinc ions or in an
CC       acidic environment. Cleavage reduces binding of HRG to heparan sulfate,
CC       but enhances the ability of HRG to bind and tether plasminogen to the
CC       cell surface. On platelet activation, releases a 33 kDa antiangiogenic
CC       peptide which encompasses the HRR. Also cleaved in the C-terminal by
CC       plasmin (By similarity). {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF194029; AAG28417.1; -; mRNA.
DR   EMBL; AB055895; BAB33092.1; -; mRNA.
DR   EMBL; AB055896; BAB33093.1; -; mRNA.
DR   EMBL; BC089779; AAH89779.1; -; mRNA.
DR   RefSeq; NP_001316829.1; NM_001329900.1.
DR   RefSeq; NP_596919.1; NM_133428.2.
DR   AlphaFoldDB; Q99PS8; -.
DR   SMR; Q99PS8; -.
DR   IntAct; Q99PS8; 6.
DR   STRING; 10116.ENSRNOP00000072623; -.
DR   MEROPS; I25.022; -.
DR   MEROPS; I25.025; -.
DR   GlyCosmos; Q99PS8; 5 sites, No reported glycans.
DR   GlyGen; Q99PS8; 5 sites.
DR   iPTMnet; Q99PS8; -.
DR   PhosphoSitePlus; Q99PS8; -.
DR   PaxDb; 10116-ENSRNOP00000049290; -.
DR   GeneID; 171016; -.
DR   GeneID; 681544; -.
DR   KEGG; rno:171016; -.
DR   KEGG; rno:681544; -.
DR   AGR; RGD:1594092; -.
DR   AGR; RGD:619808; -.
DR   CTD; 3273; -.
DR   CTD; 681544; -.
DR   RGD; 619808; Hrg.
DR   eggNOG; ENOG502S50D; Eukaryota.
DR   HOGENOM; CLU_575637_0_0_1; -.
DR   InParanoid; Q99PS8; -.
DR   OrthoDB; 5324439at2759; -.
DR   PhylomeDB; Q99PS8; -.
DR   TreeFam; TF333729; -.
DR   Reactome; R-RNO-114608; Platelet degranulation.
DR   Reactome; R-RNO-75205; Dissolution of Fibrin Clot.
DR   PRO; PR:Q99PS8; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000001809; Expressed in liver and 14 other cell types or tissues.
DR   ExpressionAtlas; Q99PS8; baseline and differential.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0005576; C:extracellular region; ISO:RGD.
DR   GO; GO:0004869; F:cysteine-type endopeptidase inhibitor activity; IEA:InterPro.
DR   GO; GO:0020037; F:heme binding; ISS:UniProtKB.
DR   GO; GO:0043395; F:heparan sulfate proteoglycan binding; ISS:UniProtKB.
DR   GO; GO:0008201; F:heparin binding; ISS:UniProtKB.
DR   GO; GO:0019865; F:immunoglobulin binding; ISS:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; ISS:UniProtKB.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; ISO:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; ISS:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0061844; P:antimicrobial humoral immune response mediated by antimicrobial peptide; ISO:RGD.
DR   GO; GO:0050832; P:defense response to fungus; ISS:UniProtKB.
DR   GO; GO:0042730; P:fibrinolysis; ISO:RGD.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; ISS:UniProtKB.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISS:UniProtKB.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; ISS:UniProtKB.
DR   GO; GO:0033629; P:negative regulation of cell adhesion mediated by integrin; ISS:UniProtKB.
DR   GO; GO:0030308; P:negative regulation of cell growth; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:2001027; P:negative regulation of endothelial cell chemotaxis; ISS:UniProtKB.
DR   GO; GO:0051918; P:negative regulation of fibrinolysis; ISO:RGD.
DR   GO; GO:0010593; P:negative regulation of lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:1900747; P:negative regulation of vascular endothelial growth factor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; ISS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:2000504; P:positive regulation of blood vessel remodeling; ISS:UniProtKB.
DR   GO; GO:0051894; P:positive regulation of focal adhesion assembly; ISS:UniProtKB.
DR   GO; GO:0002839; P:positive regulation of immune response to tumor cell; ISS:UniProtKB.
DR   GO; GO:0032956; P:regulation of actin cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0030193; P:regulation of blood coagulation; ISS:UniProtKB.
DR   GO; GO:0010468; P:regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0050730; P:regulation of peptidyl-tyrosine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0010543; P:regulation of platelet activation; ISS:UniProtKB.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; ISS:UniProtKB.
DR   CDD; cd00042; CY; 1.
DR   Gene3D; 3.10.450.10; -; 2.
DR   InterPro; IPR000010; Cystatin_dom.
DR   InterPro; IPR046350; Cystatin_sf.
DR   InterPro; IPR050735; Kininogen_Fetuin_HRG.
DR   PANTHER; PTHR13814; FETUIN; 1.
DR   PANTHER; PTHR13814:SF3; HISTIDINE-RICH GLYCOPROTEIN; 1.
DR   SMART; SM00043; CY; 2.
DR   SUPFAM; SSF54403; Cystatin/monellin; 1.
PE   1: Evidence at protein level;
KW   Blood coagulation; Cleavage on pair of basic residues; Copper;
KW   Disulfide bond; Fibrinolysis; Glycoprotein; Hemostasis; Heparin-binding;
KW   Metal-binding; Phosphoprotein; Reference proteome; Repeat; Secreted;
KW   Signal; Zinc.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..525
FT                   /note="Histidine-rich glycoprotein"
FT                   /id="PRO_0000408508"
FT   DOMAIN          19..122
FT                   /note="Cystatin 1"
FT   DOMAIN          135..240
FT                   /note="Cystatin 2"
FT   REGION          41..84
FT                   /note="Interaction with ATP5F1A"
FT                   /evidence="ECO:0000250"
FT   REGION          275..445
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        275..289
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        342..399
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        430..445
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            439..440
FT                   /note="Cleavage; by plasmin"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         438
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        112
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        123
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        200
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        322
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        330
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        24..504
FT                   /evidence="ECO:0000250"
FT   DISULFID        78..89
FT                   /evidence="ECO:0000250"
FT   DISULFID        103..124
FT                   /evidence="ECO:0000250"
FT   DISULFID        201..414
FT                   /evidence="ECO:0000250"
FT   DISULFID        216..239
FT                   /evidence="ECO:0000250"
FT   CONFLICT        6
FT                   /note="T -> A (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="V -> I (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93..98
FT                   /note="MRTSEV -> RWTSEI (in Ref. 1; AAG28417 and 2;
FT                   BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        133..134
FT                   /note="YI -> LS (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        143..145
FT                   /note="VDS -> FDF (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        165
FT                   /note="A -> E (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="S -> L (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        184
FT                   /note="M -> G (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        191
FT                   /note="S -> N (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        211
FT                   /note="P -> L (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        215
FT                   /note="L -> F (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218..224
FT                   /note="VVLTYST -> ALLSYSI (in Ref. 1; AAG28417 and 2;
FT                   BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        237..238
FT                   /note="LI -> VT (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        242
FT                   /note="F -> V (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="H -> R (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339..348
FT                   /note="Missing (in Ref. 1; AAG28417 and 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        374
FT                   /note="H -> R (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        381..385
FT                   /note="QHPHG -> HHLHR (in Ref. 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        384
FT                   /note="H -> R (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        421..425
FT                   /note="Missing (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        429
FT                   /note="R -> Q (in Ref. 1; AAG28417)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        479
FT                   /note="I -> S (in Ref. 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        494
FT                   /note="R -> Q (in Ref. 2; BAB33093)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        510
FT                   /note="G -> S (in Ref. 2; BAB33093)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   525 AA;  59049 MW;  38290A631FAC7777 CRC64;
     MKVLTTALLL VTLQCSHALS PTNCDASKPL AEKVLDLINK GRRSGYTFQL LRVSDAHLDR
     VETATIYYLV LDVVESDCWV LSTKAQDECL PAMRTSEVVI GQCKVIATRY SNESQDLSVN
     GYNCTMRSVS SAYINTKDSP VLVDSFEDSE PYRKLARKAL DKYKAENGDF ASFRVERAER
     VIRMRGGERT SYFIEFSVRN CSTQHFPRHP PVFGLCRVVL TYSTEASDLE TPEYTDLICE
     VFNTEDLKNR SDMKPHRGHE HPHCDKHLCK LSGPRDHHHT HKTHEIGCPP PPEGKDNSDR
     PPLQEGALPQ MLPGHSGPSG TNRSHRPPHN HSCNEHPCHG QHPHGHHPHG QHPHGHHPHG
     QHPHGHHPHG QHPHGHHPHG QHPHGHHPHG HHPHGDHPHG HHPHGHDFLD YGPCDPPSNS
     QELKGQYHRG HGPPHGHSRK RGPGKGLFPF HQRQIGYVYR LPPLNVGEVL TPPEANFPIF
     SLPNCNRPPQ PEIRPFPQTA SKSCPGKFEG KFPQVSNFFE HTPPK
//
